BIOMARKER:

CDKN2A deletion

News alerts, weekly reports and conference planners

Entrez ID:

1029

Related biomarkers:

‹

›

CDKN2A deletion	B Acute Lymphoblastic Leukemia	CDKN2A deletion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CDKN2A deletion	Mantle Cell Lymphoma	CDKN2A deletion	Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
CDKN2A deletion	Acute Lymphocytic Leukemia	CDKN2A deletion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CDKN2A deletion	Melanoma	CDKN2A deletion	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A deletion	Gallbladder Cancer	CDKN2A deletion	Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A deletion	Glioma	CDKN2A deletion	Glioma	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Resistant : C3	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Resistant : C3
CDKN2A deletion	Hepatocellular Cancer	CDKN2A deletion	Hepatocellular Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CDKN2A deletion	Melanoma	CDKN2A deletion	Melanoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDKN2A deletion	Pancreatic Cancer	CDKN2A deletion	Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A deletion	Gastric Adenocarcinoma	CDKN2A deletion	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A deletion	Diffuse Large B Cell Lymphoma	CDKN2A deletion	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3
CDKN2A deletion	Prolymphocytic Leukemia	CDKN2A deletion	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D
CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D
CDKN2A deletion	Ewing Sarcoma	CDKN2A deletion	Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
CDKN2A deletion	Ewing Sarcoma	CDKN2A deletion	Ewing Sarcoma	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
CDKN2A deletion	Renal Cell Carcinoma	CDKN2A deletion	Renal Cell Carcinoma	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D
CDKN2A deletion	Pancreatic Ductal Adenocarcinoma	CDKN2A deletion	Pancreatic Ductal Adenocarcinoma	BET inhibitor + CDK inhibitor Sensitive: D – Preclinical BET inhibitor + CDK inhibitor Sensitive : D	BET inhibitor + CDK inhibitor Sensitive: D – Preclinical BET inhibitor + CDK inhibitor Sensitive : D
CDKN2A deletion	HER2 Positive Breast Cancer	CDKN2A deletion	HER2 Positive Breast Cancer	abemaciclib + tucatinib Sensitive: D – Preclinical abemaciclib + tucatinib Sensitive : D	abemaciclib + tucatinib Sensitive: D – Preclinical abemaciclib + tucatinib Sensitive : D
CDKN2A deletion	Pancreatic Ductal Adenocarcinoma	CDKN2A deletion	Pancreatic Ductal Adenocarcinoma	palbociclib + JQ-1 Sensitive: D – Preclinical palbociclib + JQ-1 Sensitive : D	palbociclib + JQ-1 Sensitive: D – Preclinical palbociclib + JQ-1 Sensitive : D

CDKN2A deletion

Associations